
    
      Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in one
      cycle.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating
      factor (125ug/mÂ² per day) will be executed from day 1 to day 14 in this cycle. Another
      metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
      Efficacy evaluation,especially abscopal effect evaluation, will be conducted at the end of
      therapy and every month after that. Adverse events will be recorded according to NCI-CTC
      version 4.03.
    
  